GELS (gelteq.com) Earnings per share growth this year

Gelteq Limited develops innovative drug delivery gels, creating significant intrigue surrounding its clinical trials. The YoY earnings per share growth rate on the GURU.Markets platform captures the dynamics of this process, where the 0.00 mark indicates the level of efficiency. The business potential relies on B2B contracts and royalties, while complex certification barriers and unique patents serve as defensive assets.

GELS (Gelteq) Earnings per share growth in current year history from 10/30/2024 to 11/15/2026

Financial and market metric breakdowns for Gelteq (GELS)

- stock value and consensus price forecast:

Market Price Gelteq Ltd|GELS - Analyst Consensus Forecast

- business market valuation indicators:

Market Capitalization Gelteq Ltd|GELS - Real Price to Acquire Entire Company

- book capitalization information:

Accounting Value of a Share Gelteq|GELS - Company Book Value|Market Capitalization to Net Assets gelteq.com|GELS - Company Total Assets

- debt and solvency information:

- net income and valuation multiples indicators:

GELS - Net Profit|Projected Net Profit Gelteq Limited|GELS - P/E Multiple|Projected Price to Earnings Ratio Gelteq Limited Inc|GELS - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Gelteq Ltd|GELS - Operating profit before deduction of amortization|Earnings per share for the last four quarters Gelteq|GELS - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months gelteq.com|GELS - Earnings per share growth in current year|Net earnings per one share growth forecast for next year Gelteq Limited

- revenue and sales proceeds data:

GELS - Company Sales|Company Future Revenue Gelteq Limited Inc|GELS - Price-to-Revenue Ratio|Price-to-Projected Revenue Ratio Gelteq|GELS - Sales Growth YoY (TTM)

Basic company analysis:gelteq.com (GELS)

Investors often overstate expectations while ignoring the actual financial stability of Gelteq Limited (GELS). This indicator captures the percentage deviation of current earnings per share from the same period last year. By analyzing EPS dynamics compared to the previous year, one can assess the effectiveness of the business scaling. Growth in this metric confirms the commercial success of the unique gel drug delivery technology. The positive trend indicates the creation of an unrivaled market advantage.

Main competitors